West Yorkshire health leaders welcome new national cancer plan but warn delivery will be ‘crucial’ for families.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study, published in the International Journal of Molecular Science ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Modelling indicates that over a 20-year period, a national screening programme could detect around 9,000 lung cancers and potentially save more than 6,000 lives – an estimated 300 lives each year.

Radiation therapy is a cornerstone of lung cancer treatment. But even when delivered with precision, radiation can damage healthy lung tissue. "Try as we might, when we deliver radiation to a cancer, ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

Researchers at Wake Forest University School of Medicine developed engineered immune cells that can cross the blood-brain barrier and slow lung cancer brain metastases, offering a promising new ...

As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...

Last year, the Iowa Legislature took an important first step by passing legislation directing a comprehensive study into what ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.